Cellectar says iopofosine I-131 posts 79.2% major response rate in Phase 2 CLOVER-WaM subgroup after BTK inhibitors

Cellectar Biosciences

Cellectar Biosciences

CLRB

0.00
  • Cellectar Biosciences will present new Phase 2b CLOVER WaM subgroup results at ASCO on June 1, 2026.
  • The analysis showed strong, durable responses for iopofosine I 131 in relapsed or refractory Waldenström macroglobulinemia following BTK inhibitor therapy.
  • Tolerability was described as manageable, with severe side effects limited to blood-count reductions.
  • The data supported a plan to seek US accelerated approval, with a Phase 3 confirmatory trial targeted for 4Q26.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.